AstraZeneca is currently conducting a Phase IIIb study titled ‘Capivasertib+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients ...

This study could significantly impact AstraZeneca’s market position by potentially validating a more effective treatment regimen for T2DM, which may enhance investor confidence.

(RTTNews) - AstraZeneca Plc.'s (AZN.L, AZN) triple-combination inhaler, Breztri Aerosphere, has shown positive results in late-stage clinical trials for patients with uncontrolled asthma. The ...

The company plans to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues. AstraZeneca noted that it will maintain its strategic ...